Velicept Announces Positive Top-Line Ph2b Results for Solabegron OAB
28 Mar 2019 //
BUSINESSWIRE
Overactive bladder biotech Urovant Sciences sets terms for $150 million IPO
17 Sep 2018 //
NASDAQ
28 Mar 2019 //
BUSINESSWIRE
17 Sep 2018 //
NASDAQ